You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma after 3 or more treatment lines [ID6549]

  • Topic selection
  • Project information
  • Project documents

35154-Anitocabtagene-Autoleucel-for-Multiple-Myeloma-V1.0-DEC2024-NON-CONF.pdf

Back to top